H. Tanaka

发表

CD40 and IFN-gamma dependent T cell activation by human bronchial epithelial cells.

S. Sone, K. Maeda, M. Azuma, 2001, Journal of Medical Investigation.

MA 19.01 A Phase II Study of Nivolumab: A Multicenter, Open-Label, Single Arm Study in Malignant Pleural Mesothelioma (MERIT)

M. Okada, Y. Ohe, T. Kijima, 2017 .

[Adjuvant chemotherapy with MVP-CAB (methotrexate, vincristine, cisplatinum, cyclophosphamide, adriamycin and bleomycin) for epithelial tumors of the upper urinary tract].

Y. Murata, A. Fujii, H. Tanaka, 1992, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

Systematic analysis of acid, neutral and basic drugs in horse plasma by combination of solid-phase extraction, non-aqueous partitioning and gas chromatography-mass spectrometry.

T. Shinohara, H. Tanaka, A. Takeda, 2001, Journal of chromatography. B, Biomedical sciences and applications.

[Chemotherapy for unresectable recurrent or metastatic squamous cell carcinomas of the head and neck].

H. Nishino, K. Ichimura, T. Kanazawa, 2000, Nihon Jibiinkoka Gakkai kaiho.

[Treatment of newly diagnosed stage D2 prostatic carcinoma with hormonal therapy alone, or chemotherapy agents in combination with hormones].

A. Fujii, K. Yamanaka, H. Tanaka, 1991, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

A case with small cell carcinoma of the esophagus: measurement of tumor markers, including pro-gastrin-releasing peptide.

S. Sone, F. Ogushi, K. Izumi, 1998, Anticancer research.

[Fundamental study of combination chemotherapy with THP, 5-FU and CDDP for human KB carcinoma cell line and its multidrug resistant cell line KB-C1--usefulness of treatment with 5-FU preceding CDDP].

H. Kishimoto, M. Urade, K. Moridera, 2001, Gan to kagaku ryoho. Cancer & chemotherapy.

2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC

H. Wakelee, C. Zhou, M. Das Thakur, 2021, Annals of Oncology.

1O IMpower010: ctDNA status in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC)

B. Nabet, H. Wakelee, J. Hamm, 2022, Immuno-Oncology and Technology.